Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the enrollment of the first patient in the Phase 3 FALCON trial of bardoxolone methyl (bardoxolone) in patients with autosomal dominant polycystic kidney disease...
The Development Operations Centre supports the development of AstraZeneca’s innovative medicines and hosts clinical trial experts focussed on core therapeutic areas: oncology, cardiovascular, renal and metabolism, and respiratory AstraZeneca has launched its clinical...
May 30, 2019 01:00 UTC Results Confirm the Efficacy of CureApp’s Nicotine Dependence Treatment Application TOKYO–(BUSINESS WIRE)– Results from the world’s first randomized control study to examine digital therapeutic smoking cessation programs were...
– Data to be presented at the American Society of Clinical Oncology Annual Meeting – – Underscores importance of genetic testing to guide precision medicine treatment and improve family screening Researchers from Invitae (NYSE: NVTA), a leading...
The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the 2018 edition of Meds Pipeline Monitor. This annual publication provides a snapshot of the new...
Stellarex is the only low-dose [1] drug-coated balloon (DCB) to demonstrate a significant treatment effect and high safety profile through 3 years ILLUMENATE Pivotal trial showcases durable primary patency (maintained blood flow) in the most complex patient pool...
Email
Text